Predictive role of repair enzymes in the efficacy of Cisplatin combinations in pancreatic and lung cancer.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Anticancer Research

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 24403499
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• ERCC1 isoform expression and DNA repair in non-small-cell lung cancer.

  2013cited by this paper
• Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer.

  2013cited by this paper
• DNA-Bound Platinum Is the Major Determinant of Cisplatin Sensitivity in Head and Neck Squamous Carcinoma Cells

  2013cited by this paper
• Prognostic factors in gemcitabine–cisplatin polychemotherapy regimens in pancreatic cancer: XPD‐Lys751Gln polymorphism strikes back

  2013cited by this paper
• Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin.

  2012cited by this paper
• EGF receptor-targeted therapy in non-small-cell lung cancer: role of germline polymorphisms in outcome and toxicity.

  2012cited by this paper
• Pharmacogenetics of conventional chemotherapy in non-small-cell lung cancer: a changing landscape?

  2012cited by this paper
• Cancer statistics, 2012

  2012cited by this paper
• Molecular targets of gemcitabine action: rationale for development of novel drugs and drug combinations.

  2012cited by this paper
• The potential of exploiting DNA-repair defects for optimizing lung cancer treatment

  2012cited by this paper
• Role of DNA repair gene polymorphisms in the efficiency of platinum-based adjuvant chemotherapy for non-small cell lung cancer.

  2011cited by this paper
• Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis

  2011cited by this paper
• Thymidylate Synthase and Excision Repair Cross-Complementing Group-1 as Predictors of Responsiveness in Mesothelioma Patients Treated with Pemetrexed/Carboplatin

  2011cited by this paper
• Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy.

  2011cited by this paper
• FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

  2011cited by this paper
• The platinum-based treatments for advanced non-small cell lung cancer, is low/negative ERCC1 expression better than high/positive ERCC1 expression? A meta-analysis.

  2010cited by this paper
• Pharmacogenomics in non-small-cell lung cancer chemotherapy.

  2009cited by this paper
• Immunodetection of DNA repair endonuclease ERCC1-XPF in human tissue.

  2009cited by this paper
• Correlation of CDA, ERCC1, and XPD Polymorphisms with Response and Survival in Gemcitabine/Cisplatin–Treated Advanced Non–Small Cell Lung Cancer Patients

  2008cited by this paper
• ERCC1 codon 118 polymorphism is a useful prognostic marker in patients with pancreatic cancer treated with platinum-based chemotherapy.

  2008cited by this paper
• Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.

  2008cited by this paper
• ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine.

  2006cited by this paper
• DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.

  2006cited by this paper
• Effects of gemcitabine on cis-platinum-DNA adduct formation and repair in a panel of gemcitabine and cisplatin-sensitive or -resistant human ovarian cancer cell lines.

  2006cited by this paper
• RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer.

  2006cited by this paper
• Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.

  2005cited by this paper
• Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial.

  2005cited by this paper
• Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer.

  2004cited by this paper
• American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003.

  2004cited by this paper
• Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy.

  2004cited by this paper
• XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy.

  2004cited by this paper
• Effect of gemcitabine and cis-platinum combinations on ribonucleotide and deoxyribonucleotide pools in ovarian cancer cell lines.

  2003cited by this paper
• Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines.

  2003cited by this paper
• Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975.

  2003cited by this paper
• Pharmacogenetics goes genomic

  2003cited by this paper
• Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer.

  2002cited by this paper
• Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.

  2002cited by this paper
• Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene.

  2000cited by this paper
• Schedule-dependent pharmacodynamic effects of gemcitabine and cisplatin in mice bearing Lewis lung murine non-small cell lung tumours.

  2000cited by this paper
• Expression of ERCC1 antisense RNA abrogates gemicitabine-mediated cytotoxic synergism with cisplatin in human colon tumor cells defective in mismatch repair but proficient in nucleotide excision repair.

  2000cited by this paper
• Scheduling of gemcitabine and cisplatin in Lewis lung tumour bearing mice.

  1999cited by this paper
• Synergistic interaction between cisplatin and gemcitabine in vitro.

  1996cited by this paper
• Schedule-dependent therapeutic efficacy of the combination of gemcitabine and cisplatin in head and neck cancer xenografts.

  1995cited by this paper
• DNA repair in humans.

  1995cited by this paper

• Wortmannin Inhibits Cell Growth and Induces Apoptosis in Colorectal Cancer Cells by Suppressing the PI3K/AKT Pathway.

  2024cites this paper
• Are we still on the right path(way)?: the altered expression of the pentose phosphate pathway in solid tumors and the potential of its inhibition in combination therapy

  2022cites this paper
• Double-staining Immunohistochemistry Reveals in Malignant Pleural Mesothelioma the Coexpression of ERCC1 and RRM1 as a Frequent Biological Event Related to Poorer Survival.

  2020cites this paper
• PNU‐74654 enhances the antiproliferative effects of 5‐FU in breast cancer and antagonizes thrombin‐induced cell growth via the Wnt pathway

  2019cites this paper
• Novel targeted strategies to overcome resistance in small-cell lung cancer: focus on PARP inhibitors and rovalpituzumab tesirine

  2019influential citation
• Synthesis of spheroid shaped silver nanoparticles using Indian traditional medicinal plant Flacourtia indica and their in vitro anti-proliferative activity

  2019cites this paper
• Predictive value of ERCC1, ERCC2, ERCC4, and glutathione S-Transferase Pi expression for the efficacy and safety of FOLFIRINOX in patients with unresectable pancreatic cancer.

  2018cites this paper
• Predictive Value of Single Nucleotide Polymorphisms of ERCC1, XPA, XPC, XPD and XPG Genes, Involved in NER Mechanism in Patients with Advanced NSCLC Treated with Cisplatin and Gemcitabine

  2018cites this paper
• Crocin synergistically enhances the antiproliferative activity of 5‐flurouracil through Wnt/PI3K pathway in a mouse model of colitis‐associated colorectal cancer

  2018cites this paper
• Association of TNF‐308 G>A polymorphism located in tumor necrosis factor a with the risk of developing cervical cancer and results of pap smear

  2018cites this paper
• The complete structure of the human TFIIH core complex

  2018cites this paper
• FIGNL1 is overexpressed in small cell lung cancer patients and enhances NCI-H446 cell resistance to cisplatin and etoposide

  2017cites this paper
• Clinical-pharmacogenetic models for personalized cancer treatment: application to malignant mesothelioma

  2017cites this paper
• Second-line chemotherapy for advanced pancreatic cancer: Which is the best option?

  2017cites this paper
• Non-invasive approaches for lung cancer diagnosis

  2017cites this paper
• Five years update on relationships between malignant pleural mesothelioma and exposure to asbestos and other elongated mineral particles

  2016cites this paper
• Single-sample expression-based chemo-sensitivity score improves survival associations independently from genomic mutations for ovarian cancer Patients

  2016cites this paper
• Cisplatin resistance and opportunities for precision medicine.

  2016cites this paper
• Genetic factors affecting patient responses to pancreatic cancer treatment

  2016cites this paper
• Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort

  2015cites this paper
• Predicting Survival After Irradiation of Metastases from Pancreatic Cancer.

  2015cites this paper
• RKIP promotes cisplatin-induced gastric cancer cell death through NF-κB/Snail pathway

  2015cites this paper
• Phase 1 trial and pharmacokinetic study of the oral platinum analog satraplatin in children and young adults with refractory solid tumors including brain tumors

  2015cites this paper
• Le point sur hENT1, autres biomarqueurs

  2015cites this paper
• Modulation of signaling enhances the efficacy of the combination of satraplatin and erlotinib.

  2014cites this paper
• Platinum(IV) cisplatin derivative trans, cis, cis-bis(heptanoato)amine(cyclohexylamine)dichloridoplatinum(IV) has an enhanced therapeutic index compared to cisplatin for the treatment of non-small cell lung cancer

  2014cites this paper